Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wellbutrin SR/Zyban Generics Will Not Be Blocked By Andrx Exclusivity

Executive Summary

Andrx will allow Teva/Impax to launch a generic version of GlaxoSmithKline's Wellbutrin SR/Zyban (bupropion sustained-release) if FDA does not approve Andrx' ANDA within a "defined period of time.
Advertisement

Related Content

Wellbutrin SR Generics Multiply As Andrx Relinquishes Exclusivity
Impax/Teva Wellbutrin SR Generic Cleared To Launch By Court, FDA
Eon Wellbutrin SR Generic Launch Delayed By Two Restraining Orders
Eon Wellbutrin SR Generic Launch Could Slow GSK Conversion Efforts
Wellbutrin SR Patent Needs Further Review, Appeals Court Agrees With GSK
GSK Wellbutrin XL Approval Pressures Generics to Launch SR Formulation
Pfizer Zoloft “Authorized” Generic Will Be Available From Ivax By Mid-2006
Wellbutrin SR Patent Cases: Did GSK Surrender Claims To Excipients?
Naprelan Generic Exclusivity Settled; Andrx Sees Three Near-Term Launches
Naprelan Generic Exclusivity Settled; Andrx Sees Three Near-Term Launches
Advertisement
UsernamePublicRestriction

Register

PS042258

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel